A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia
Latest Information Update: 27 Apr 2022
At a glance
- Drugs Moxetumomab pasudotox (Primary)
- Indications Hairy cell leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 19 Feb 2020 Results (n=123) of a pooled analysis of data from 2 trials (Study 1001 and Study 1053) assessing pharmacokinetics of moxetumomab pasudotox in adults with relapsed or refractory Hairy Cell Leukemia published in the British Journal of Clinical Pharmacology.
- 02 Jan 2020 According to a Innate Pharma media release, the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Lumoxiti (moxetumomab pasudotox-tdfk) for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog, based on the final analysis of this study.
- 08 Dec 2019 Final analysis and long-term results presented in an Innate Pharma media release.